Sanofi SA revealed on Thursday that its net sales in the first quarter of the fiscal year 2026 saw an annual rise of 6.2% and 13.6% at the constant exchange rate (CER), to reach €10.5 billion.
The company's net income, calculated according to the International Financial Reporting Standards (IFRS), came in at €1.6 billion, and its IFRS earnings per share (EPS) at €1.34, down 11.8% on a yearly basis. Meanwhile, its business net income rose by 2.4%, or 11.1% at CER, to €2.3 billion, and its business EPS jumped by 5% and14% at CER, to €1.88. In the first quarter, Sanofi's gross profit rose 6.1% and 14.4% at CER, to €8.2 billion.
"We had a strong start to 2026 with double-digit sales and business EPS growth. Sales increased by 13.6%, supported by Pharma launches and recent acquisitions ... We obtained five regulatory approvals, all in immunology, achieved one positive phase 3 study readout for venglustat in rare diseases, and reported encouraging phase 2 data for lunsekimig in respiratory diseases," Interim CEO Olivier Charmeil said.
https://breakingthenews.net/Article/Sanofi's-Q1-net-sales-up-by-6.2-to-euro10.5-billion/66130413
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.